Chengdu Kanghong Pharmaceutical Group (002773) Stock Overview
Engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
002773 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Chengdu Kanghong Pharmaceutical Group Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥28.05 |
| 52 Week High | CN¥47.37 |
| 52 Week Low | CN¥24.50 |
| Beta | 0.11 |
| 1 Month Change | 0.50% |
| 3 Month Change | -18.29% |
| 1 Year Change | 7.10% |
| 3 Year Change | 44.59% |
| 5 Year Change | 38.25% |
| Change since IPO | 178.93% |
Recent News & Updates
Recent updates
Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Shares Bounce 30% But Its Business Still Trails The Market
Mar 28
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Looks Inexpensive But Perhaps Not Attractive Enough
Jan 03With EPS Growth And More, Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Makes An Interesting Case
Dec 12Insufficient Growth At Chengdu Kanghong Pharmaceutical Group Co., Ltd (SZSE:002773) Hampers Share Price
Sep 15Here's Why We Think Chengdu Kanghong Pharmaceutical Group (SZSE:002773) Is Well Worth Watching
Jun 21Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Price Is Right But Growth Is Lacking After Shares Rocket 40%
May 12Lacklustre Performance Is Driving Chengdu Kanghong Pharmaceutical Group Co., Ltd's (SZSE:002773) Low P/E
Mar 27Shareholder Returns
| 002773 | CN Pharmaceuticals | CN Market | |
|---|---|---|---|
| 7D | -2.1% | -0.4% | 4.9% |
| 1Y | 7.1% | 13.5% | 32.2% |
Return vs Industry: 002773 underperformed the CN Pharmaceuticals industry which returned 13.9% over the past year.
Return vs Market: 002773 underperformed the CN Market which returned 31.6% over the past year.
Price Volatility
| 002773 volatility | |
|---|---|
| 002773 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 5.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in CN Market | 10.2% |
| 10% least volatile stocks in CN Market | 4.1% |
Stable Share Price: 002773 has not had significant price volatility in the past 3 months compared to the CN market.
Volatility Over Time: 002773's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 4,462 | Xiao Ke | www.cnkh.com |
Chengdu Kanghong Pharmaceutical Group Co., Ltd engages in the research, development, manufacture, and distribution of medicine for ophthalmic, neuropsychiatric and other applications in China. It also develops a pipeline of clinical and pre-clinical programs for ophthalmology, CNS, oncology, and common disease. The company was founded in 1996 and is based in Chengdu, China.
Chengdu Kanghong Pharmaceutical Group Co., Ltd Fundamentals Summary
| 002773 fundamental statistics | |
|---|---|
| Market cap | CN¥25.84b |
| Earnings (TTM) | CN¥1.25b |
| Revenue (TTM) | CN¥4.67b |
Is 002773 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 002773 income statement (TTM) | |
|---|---|
| Revenue | CN¥4.67b |
| Cost of Revenue | CN¥474.60m |
| Gross Profit | CN¥4.19b |
| Other Expenses | CN¥2.94b |
| Earnings | CN¥1.25b |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
Apr 23, 2026
| Earnings per share (EPS) | 1.36 |
| Gross Margin | 89.83% |
| Net Profit Margin | 26.80% |
| Debt/Equity Ratio | 0% |
How did 002773 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/10 06:45 |
| End of Day Share Price | 2026/04/10 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Chengdu Kanghong Pharmaceutical Group Co., Ltd is covered by 8 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Ziyu He | China International Capital Corporation Limited |
| Xiao Wei Lin | Everbright Securities Co. Ltd. |
| Richard L. Yeh | Goldman Sachs |